Trials / Suspended
SuspendedNCT00197483
Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia
Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia
- Status
- Suspended
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (planned)
- Sponsor
- Hamamatsu University · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pergolide (drug) |
Timeline
- Start date
- 2003-03-01
- First posted
- 2005-09-20
- Last updated
- 2005-09-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00197483. Inclusion in this directory is not an endorsement.